Dare Bioscience reports FY2022 cash $34.7M; XACIATO first commercial sale expected Q2 2023

Dare Bioscience, Inc.

Cash and cash equivalents $34.7M at Dec 31, 2022, down from $51.7M at Dec 31, 2021.
G&A expenses $11.2M (FY2022) vs $8.4M (FY2021); R&D expenses $30.0M vs $30.6M.
Received $24.1M in non-dilutive funding in 2022: $10M from Organon license, $13.3M grants, $0.8M Australian rebate.
XACIATO first commercial sale expected Q2 2023, triggering $2.5M milestone to Dare.
Sildenafil Cream Phase 2b topline data targeted for Q2 2023; Ovaprene pivotal study initiation mid-2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Dare Bioscience, Inc. reported financial results for the quarter and fiscal-year ended December 31, 2022.

Period: the quarter and fiscal-year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 30, 2023, Daré Bioscience, Inc. issued a press release announcing its financial results for the quarter and fiscal-year ended December 31, 2022

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Dare Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-009600

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.